University of Chicago
University of Chicago
Chicago, Illinois, United States
Dr. Randy Sweis is a physician-scientist who specializes in the treatment of patients using leading-edge immunotherapies and novel investigational approaches. Dr. Sweis has clinical expertise in phase I trials for advanced solid tumors with a focus on genitourinary malignancies. He has served as a Principal Investigator on over 30 clinical trials, including TCR based therapies, intratumoral immunotherapies, checkpoint therapy, cytokine therapy, microbiome-modifying approaches, and viral-, vaccine-, and RNA-based therapies. His laboratory research employs preclinical modeling of solid tumors and computational methods to identify and circumvent mechanisms of resistance to cancer immunotherapies and enhance the immune response against cancer.
Disclosure(s): Contract Research: Abbvie (Ongoing); Ascendis (Ongoing); Astellas (Ongoing); Astra Zeneca (Ongoing); BMS (Ongoing); CytomX (Ongoing); Eisai (Ongoing); EMD Serono (Ongoing); Genentech/Roche (Ongoing); Gilead (Ongoing); Immunocore (Ongoing); Lilly (Ongoing); Merck (Ongoing); Mirati Therapeutics (Ongoing); Moderna (Ongoing); Novartis (Ongoing); Pfizer (Ongoing); Pionyr (Ongoing); Pyxis Oncology (Ongoing); QED Therapeutics (Ongoing); Scholar Rock (Ongoing); Seattle Genetics (Ongoing)
Non-CE Consulting: Astellas (Ongoing); Astra Zeneca (Ongoing); Aveo (Ongoing); BMS (Ongoing); Editas (Ongoing); Eisai (Ongoing); EMD Serono (Ongoing); Exelixis (Ongoing); Gilead (Ongoing); Janssen (Ongoing); Lilly (Ongoing); Mirati Therapeutics (Ongoing); Pfizer (Ongoing); Seattle Genetics (Ongoing); Silverback (Ongoing)
Ownership Interest: I own stocks of the Commercial entity: Abbvie (Ongoing)